{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 1 of 74', 'Clinical Trial Protocol', 'Interim,', '2', 'U', 'Trial Title:', 'INTERIM: a randomised phase II feasibility study of', 'INTERmittent versus continuous dosing of oral targeted', 'combination therapy In patients with BRAFV600 mutant stage 3', 'unresectable or metastatic Melanoma', 'Protocol Number:', 'INTERIM17', 'EudraCT Number:', '2016-005228-27', 'ISRCTN Number:', '18183156', 'NIHR Portfolio CPMS: 33584', 'Investigational Product: Dabrafenib & Trametinib', 'Protocol Version:', 'V1.1', 'Chief Investigator:', 'Pippa Corrie', 'CI Address:', 'Oncology Centre, Box 193,', \"Addenbrooke's Hospital\", 'Hills Road', 'Cambridge', 'CB2 0QQ', 'Telephone:', '01223 274401', 'Trial Sponsor:', 'Cambridge University Hospital NHS Foundation Trust', 'R&D Department, Box 277', \"Addenbrooke's Hospital\", 'Hills Road', 'Cambridge', 'CB2 OQQ', 'SAE Reporting:', 'INTERIM Clinical Trial Coordinator', 'Direct Line: 01223 216674', 'Fax: 01223 586839', 'Email: cctu.cancer@addenbrookes.nhs.u', 'An NCRI Skin Cancer Clinical Studies Group Trial', 'Cambridge Cancer Centre', 'NHS', 'CANCER', 'CAMBRIDGE', 'RESEARCH', 'CENTRE', '53', 'Oxford Health', 'Funded by', 'CANCER', 'UK', 'UNIVERSITY OF', 'NIHR', 'RESEARCH', 'NHS Foundation Trust', '-', 'UNIVERSITYOF', 'Cambridge University Hospitals NHS', 'UK', 'CAMBRIDGE', 'NHS Foundation Trust', 'OXFORD', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 2 of 74', '1', 'Protocol Signatures:', 'I give my approval for the attached protocol entitled INTERIM: a randomised phase II', 'feasibility study of INTERmittent versus continuous dosing of oral targeted in patients', 'with BRAF mutant unresectable or metastatic Melanoma dated 21st September 2017', 'Chief Investigator', 'Name:', 'Signature:', 'Date:', 'Site Signatures', 'I have read the attached protocol entitled INTERIM: a randomised phase II feasibility', 'study of INTERmittent versus continuous dosing of oral targeted in patients with BRAF', 'mutant unresectable or metastatic Melanoma dated 21st September 2017 and agree to', 'abide by all provisions set forth therein.', 'I agree to comply with the conditions and principles of Good Clinical Practice as outlined', 'in the European Clinical Trials Directives 2001/20/EC and the GCP Directive', '2005/28/EC, the Medicines for Human Use (Clinical Trials) Regulations 2004 (SI', '2004/1031) and any subsequent amendments of the clinical trial regulations, the', \"Sponsor's SOPs, and other regulatory requirements as amended.\", 'I agree to ensure that the confidential information contained in this document will not', 'be used for any other purpose other than the evaluation or conduct of the clinical', 'investigation without the prior written consent of the Sponsor', 'Principal Investigator', 'Name:', 'Signature:', 'Date:', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 3 of 74', '2', 'Trial Contacts', 'Dr Pippa Corrie', 'Cambridge University Hospital NHS Foundation Trust,', '(Chief Investigator)', 'Oncology Centre, Box 193,', \"Addenbrooke's Hospital,\", 'Cambridge,', 'CB2 OQQ,', 'Telephone: 01223 2744013', 'Email: pippa.corrie@addenbrookes.nhs.uk', 'Dr Rubeta Matin', 'Churchill Hospital', '(Qualitative Research lead)', 'Old Road,', 'Oxfordshire,', 'OX3 7LE', 'Telephone: 01865 228264', 'Email: rubeta.matin@ouh.nhs.uk', 'Ms Elizabeth Gibbons', 'Nuffield Department of Population Health', '(Qualitative Research deputy)', 'University of Oxford', 'Richard Doll Building', 'Old Road Campus', 'Oxford OX3 7LF', 'Telephone: +44 (0)1865 289402', 'Email: elizabeth.gibbons@dph.ox.ac.uk', 'Dr Sarah Wordsworth', 'Health Economics Research Centre, Nuffield', '(Health Economist)', 'Department of Population Health, University of', 'Oxford', 'Old Road Campus,', 'Headington', 'Oxfordshire,', 'OX3 7LF,', 'Telephone: 01865 289268', 'Email: sarah.wordsworth@dph.ox.ac.uk', 'Professor Mark Middleton', 'Churchill Hospital', '(Translational Research Lead)', 'Old Road,', 'Oxfordshire,', 'OX3 7LE,', 'Telephone: 01865 235315', 'Email: mark.middleton@oncology.ox.ac.uk', 'Anita Chhabra', 'Cambridge Clinical Trials Unit - Cancer Theme', '(Trial Pharmacist)', '(CCTU-CT)', 'S4, Box 279,', \"Addenbrooke's Hospital,\", 'Cambridge,', 'CB2 0QQ,', 'Telephone: 01223 596233', 'Email: anita.chhabra@addenbrookes.nhs.u', 'Dr Wendi Qian', 'Cambridge Clinical Trials Unit - Cancer Theme', '(Trial Statistician)', '(CCTU-CT)', 'S4, Box 279,', \"Addenbrooke's Hospital,\", 'Cambridge,', 'CB2 0QQ,', 'Telephone: 01223 346363', 'Email: wendi.gian@addenbrookes.nhs.uk', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}